You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

August 24, 2015

Front-of-Package Labeling in Thailand

Informed Counsel

Expanding waistlines and increasing health awareness have given rise to a consumer culture infatuated with well-being, not only in Thailand but all over the world. For producers, this means intense pressure to create healthy or healthier versions of their products. For the government—specifically the Thai Food and Drug Administration (FDA)—this means an obligation to implement and enforce stricter regulations on food and nutrition.

The Thai Perspective

As we move into an age where life is increasingly fast-paced, there is no reason why the food industry should be left behind. While nutritional labels are often displayed on the back of packaging, Front-of-Package (FOP) labeling has become popular among policy makers because it simplifies the most important information and places it where it is visible at first sight to the hurried consumer. In Thailand, the original 1998 Notification of the Ministry of Public Health (MOPH) implemented non-FOP nutritional labeling requirements which were mandatory for certain foods and voluntary for others. A survey conducted in 2009, however, concluded that the nutritional information was difficult to understand, which caused the FDA to make a number of changes.

In a series of subsequent ministerial notifications, the FDA implemented the Guideline Daily Amount (GDA) system of labeling, an FOP system that made GDA labels mandatory for snack products and certain ready-to-eat foods. The current GDA label breaks down nutritional information into four categories: calories, sugars, fats, and sodium. This requires producers to clearly state the nutrient content and percentage of recommended daily intake per package.

FOP Labeling Around the World

Countries around the world have also introduced policies which mirror the objectives of the GDA system of labeling to help consumers make the “smart” choice quickly. For example, the European Union takes the same approach as Thailand, basing its guidelines on the latest published scientific data on dietary requirements and recommendations. Similarly, the United States uses a voluntary Facts Up Front labeling system, which calls for a summary of calories, saturated fat, sodium, and sugar per serving on the front of various food and beverage products.

Singapore, on the other hand, uses the Healthier Choice Symbol, an interpretive nutrition logo which distinguishes products that are lower in saturated fat and trans fat, sodium, and sugar, but higher in whole grains, fiber, and other healthy nutrients. Nutrition guidelines are set according to each product category. There are 12 main product categories and more than 70 subcategories. In addition, there are variants including the Healthier Snack Symbol and the Healthier Ingredient Symbol.

Australia and New Zealand use the Daily Intake Guide and the Health Star Rating. The Daily Intake Guide is a voluntary scheme which uses a set of reference values for acceptable levels of intake for energy and a variety of nutrients, sugars, protein, fat, fiber, and sodium, to name a few. The Health Star Rating system was developed to make it easier for consumers to compare similarly packaged food and therefore make healthier decisions. It ranks products on a scale from half a star to five stars based on their nutritional profile which includes, for example, energy, saturated fat, and sodium. This system of labeling is a hybrid of the GDA system used by Thailand, the European Union, and the United States, as well as the Healthier Choice Symbol used by Singapore.

The Future of FOP Labeling

The food and beverage community has pushed to revamp the current FOP labeling scheme in Thailand. Currently, the National Food Committee, a subcommittee of the Thai FDA, is working to add to the present FOP GDA labeling scheme, but the additions have yet to be announced. It is known, however, that use of the new FOP label will be voluntary and presently it is only being considered for certain foods. Some organizations are looking for inspiration in the “traffic light” nutritional labeling system, a system that uses the colors red, amber, and green to indicate high, acceptable, and low levels of fat, saturated fats, sugar, and salt in various products. Foods with “green” indicators are healthier than foods with “red” indicators, while foods with “amber” indicators fall in between.

The Federation of Thai Industries Food Group has supported the use of GDA nutrition labels and is determined to become involved in educating consumers about the GDA system of labeling. It prefers the GDA system of labeling to a color-coded system or an interpretive nutritional logo because these are sometimes misleading and vague and often do not comprehensively take into account different nutritional needs.

The good news is that the industry has been invited to participate in the development of a new scheme which producers can both contribute to and benefit from. With the correct industry input, FOP labeling should offer consumers informative nutritional information that is apt for a fast-paced world.

RELATED INSIGHTS​ 

August 8, 2025
In response to persistent challenges in food safety management and recent high-profile incidents involving counterfeit supplemented foods, infant formula, and health supplements, the Ministry of Health of Vietnam is initiating comprehensive regulatory reforms. These reforms include proposed amendments to the Law on Food Safety and its implementing Decree No. 15/2018/ND-CP (Decree 15), introducing significant changes to the registration procedures for food products, especially supplemented food products and health supplements. While awaiting public consultation and approval of the amended Law on Food Safety, the Ministry of Health is developing an interim mechanism, which includes a draft decree to replace Decree 15 and a draft resolution to address urgent issues until the amended law becomes effective, expected in July 2026. To align with the new Law on Quality of Products and Goods, the draft resolution stipulates that the declaration and registration of food products will follow the following procedures: Declaration of applied standards for food products, which is currently known as the “self-declaration” procedure, applies to processed packaged foods, food additives, food processing aids, containers or utensils that come into direct contact with food, packaging materials in direct contact with food, and micronutrients. Granting of circulation numbers, which is the current “registration of product declaration” procedure, applies to specific categories of food including health supplements, medical nutrition foods, special dietary foods, nutritional products for children up to 36 months, and, especially, supplemented foods, which are currently subject to self-declaration but will be shifted to this registration procedure. In addition, the following new procedure is introduced in the draft decree: Registration of declaration of conformity, which applies to the same product category as in “declaration of applied standards” above, but is for products that are already subject to technical regulations covering both safety indicators and quality indicators. Changes to the Food Product
July 23, 2025
On June 26, 2025, the National Assembly of Vietnam adopted Resolution No. 216/2025/QH15 to extend the duration of agricultural land use tax exemption through December 31, 2030. This policy extension reaffirms the government’s ongoing efforts to support the agricultural sector, ensure national food security, and promote rural development. Key Takeaways Tax Exemption Period Extended: The new resolution continues the full exemption from agricultural land use tax as stipulated under Resolution No. 55/2010/QH12, as amended in 2016 and 2020. The tax exemption, which was originally set to expire at the end of 2025, will now remain in effect until December 31, 2030. Scope of Exemption: The exemption applies to all types of land currently eligible under the existing legal framework for agricultural land use tax relief. This typically includes land used by households, cooperatives, and non-commercial organizations for agricultural production, aquaculture, salt-making, and reforestation. Effective Date: Resolution 216 will take effect on January 1, 2026. During the interim period, tax exemption remains valid under existing laws and resolutions until the end of 2025. Implementation Guidance to Follow: The government is tasked with issuing detailed guidance to ensure effective implementation of this extended exemption. Businesses, cooperatives, and individuals engaged in agricultural activities should monitor upcoming regulations and instructions from relevant ministries. Outlook Vietnam’s extension of agricultural land use tax exemption demonstrates a strong policy commitment to rural economic stability and environmental sustainability. For land users, the exemption represents meaningful financial relief that can be reinvested into modernizing farming techniques, improving land efficiency, or transitioning to sustainable practices. While the extension itself is automatic, it is recommended that agricultural land users and stakeholders review their land use documentation and tax profiles to ensure alignment with eligibility requirements. Future implementation regulations may also introduce new compliance obligations that should be tracked closely.
July 15, 2025
On July 1, 2025, Vietnam’s Ministry of Health issued Circular No. 30/2025/TT-BYT providing updated guidance on the application of drug quality standards, testing of drugs and pharmaceutical ingredients, and procedures for the recall and handling of noncompliant drugs (Circular 30). Circular 30 officially came into effect on the same day and replaces Circular No. 11/2018/TT-BYT and its amendments. Key highlights of Circular 30 are presented below. Drug and Pharmaceutical Ingredient Quality Standards Circular 30 maintains consistency with previous regulations regarding the selection of an applicable quality specification. Pharmaceutical businesses and drug preparation establishments may still choose to apply standards from the Vietnamese Pharmacopoeia, reference pharmacopoeias (including the United States Pharmacopoeia, the European Pharmacopoeia, the British Pharmacopoeia, the Japanese Pharmacopoeia, and the International Pharmacopoeia), or an in-house specification. Priority is given to the Vietnamese Pharmacopoeia and reference pharmacopoeias, encompassing quality indicators, quality levels, and testing methods. If alternative pharmacopoeias or in-house specifications are used, they must meet the requirements outlined in the corresponding monographs of the Vietnamese or reference pharmacopoeias. At the time of registration, the quality standards of drugs and pharmaceutical ingredients must comply with either the current version of the pharmacopoeia or a previous version of the pharmacopoeia that is no more than two years older than the current version. The requirement for updating quality specifications in line with the quality under the corresponding pharmacopoeia also applies to products that have already been granted marketing authorization. Testing Drugs and Pharmaceutical Ingredients in Quality Management Similar to the regulations under the previous circular, if pharmaceutical businesses disagree with the sample testing results, they may, within five working days of receiving the test report, request that the state quality inspection authority designate an alternative testing facility. The testing period for establishments listed as foreign drug manufacturers with quality violations remains
July 14, 2025
Life sciences specialists from Tilleke & Gibbins have updated the firm’s guide to pharmaceutical data exclusivity regulations and practices in Southeast Asia. This guide contains quick-reference information on the availability of data exclusivity protections and limitations in Cambodia, Indonesia, Laos, Malaysia, Myanmar, Thailand, and Vietnam. Developing and launching a new drug on a commercial scale requires an enormous amount of time and investment in research and development (R&D), including pre-clinical testing and clinical trials. When considering the aggregate amount of drug development costs, it is important to recognize that this includes not only the investment in developing new drugs that get approved by a government food and drug regulator and are successfully brought to market, but also the R&D expenditures on a large number of potential pharmaceutical compounds and products that never actually make it to market. In particular, considerable investment is required in order to conduct and produce clinical trial data—to prove safety, efficacy and effectiveness of a new drug—that would warrant marketing approval by the regulatory authority. Such data is proprietary in nature and highly valuable for a research-based pharmaceutical company that develops an original drug. On the other hand, patent law typically confers generic drug manufacturers with the ability to engage in various preparatory activities with a view to obtaining marketing approval for a generic product before the patent for the original drug expires (commonly known as a “Bolar provision”). Since a generic drug maker may submit an application for marketing approval of a generic product before the relevant patent expires, the extent to which the drug originator’s data submitted to the regulatory authority is protected—or in other words, the extent to which the generic company may rely on the drug originator’s previously filed data, which underpins the safety and efficacy of the drug, to support